



ASIA PACIFIC HEALTHTECH INVESTMENT LANDSCAPE

HALF YEAR 2020

- Asia Pacific Insights
- Our Point of View
- China Investment Trends
- South Asia Investment Trends
- SEA Investment Trends
- NEA Investment Trends
- ANZ Investment Trends



OUR GLOBAL DIGITAL HEALTH ECOSYSTEMS COVERAGE



3 CONTINENTS
Asia | USA | Europe

4 REGIONS
Asia | USA |
Europe | Middle East

31 COUNTRIES

Startups

6300+

Investors

4000+

Partnerships

8000+

Corporates

5000+

Cumulative
funding
and deals

\$80 B
FUNDING

7200
DEALS

Total number of categories and data points

16
CLUSTERS

48
CATEGORIES

70 M
DATA POINTS

Powered By:

“



JULIEN DE SALABERRY

CEO & Founder
Galen Growth

We are delighted to share with you our 2020 Asia Pac HealthTech Landscape Half Year report, the 7th edition of our bi-annual go-to-reference for ecosystem key trends and insights for investors, corporations and digital health ventures.

As we publish this report, the WHO reports over 11 million COVID-19 cases and 500,000 deaths. It is a great stress test for healthcare systems across the world and for digital health investments.

Whilst Galen Growth has witnessed a significant shift in the adoption of digital health solutions to address weakened and, at times, inadequate healthcare systems, HealthTech has seen a substantial loss of investment momentum in H1 2020 which closed at US\$1.9B invested, approximately half of H1 2019, across 171 deals, a 46% drop from last year's first six months.

Early stage and Series A total deal value shrunk by 50%, compounded further by Series B total deal value down by more than 60% and total Series C deal value collapsing by more than 80%. Appetite for mega-deals (>\$100M) was limited with a mere four deals executed.

After a very weak Q1, China's momentum recovered in Q2 with total deal value to digital health ventures in the first half breaking the \$1B mark across 52 deals. In stark contrast, both India and NE Asia investment momentum remained unaffected.

Despite these headwinds, both industry and investor sentiment in Asia Pac remains upbeat. Whereas investors chose to prioritise their existing portfolios, many corporate leaders continue to build partnerships and expect further momentum in H2.

As the crisis continues and the world copes with an ever-growing healthcare burden, an important question remains: how will the Asia Pac young innovative HealthTech startups continue their mission if venture capitalists, the managers of their investors' monies, remain shy in H2 2020?

This report is our most comprehensive report to date and is powered by HealthTech Alpha, a Galen Growth solution, the leading global digital health intelligence platform.

ASIA PACIFIC

INVESTMENT TRENDS





IN H1 2020,
ASIA PAC HEALHTECH
TOTAL FUNDING DEPLOYED WAS

\$1.9 BILLION



ACROSS

171 DEALS

ASIA PACIFIC

ASIA PAC VS USA

Driven by the earlier onset of Covid-19, compounding the impact of the US-China trade war, funding was down in APAC in Q1 but bounced back during the second quarter, while the US ecosystem seemingly remained unaffected



CAGR H1 2015- H1 2020	
USA	27%
APAC	8%
China	2%
India	38%
SEA	33%
NEA	32%

Source: HealthTech Alpha

ASIA PACIFIC


ASIA PAC HEALTHTECH FUNDING HISTORY

- The first half of 2020 HealthTech funding closed at \$1.87 B, down 46% vs H1 2019 and down 50% vs H1 2018
- The first half of 2020 saw the lowest number of deals in the past 4 years, with a 19% dip in deal activity vs the first half of 2019
- H1 2020 also saw a significant dip in its average deal size, down 33% to \$10.9M
- The first half of 2020 counted a total of 4 mega deals, down from 10 in H1 2019, which represented 41% of total funding value
- Exits (IPO & M&A) volume share was 5.3% in the first half of 2020, down 7.6% YoY

Cumulative Deal Volume by Quarter

	Q1	Q2	Q3	Q4
2017 Deals	119	264	393	530
2018 Deals	146	296	438	580
2019 Deals	108	211	310	400
2020 Deals	81	171		


Cumulative Deal Value by Quarter



ASIA PACIFIC

QOQ ASIA PACIFIC HEALTHTECH FUNDING HISTORY


- APAC HealthTech funding recorded its first two lowest quarters: a 50% decline from 2018 which recorded its highest total value with \$1.1B IPO by Ping An Hao Daifu (Good Doctor) in 2018
- The first quarter of 2020 became the 6th consecutive quarterly decline in deal volume closed across the region
- Nevertheless, Q2 2020 saw an increase in average deal value to \$12M per deal compared to \$9.4M in the first quarter of the year
- Average deal size in APAC fell to \$10.9M, down 33% YoY
- Cumulative deal value since 2017 exceeded \$18.7B



ASIA PACIFIC

ASIA PAC HEALTHTECH FUNDING BY STAGE


- Total Early stage deal value in H1 2020 dipped 7.3% compared to H1 2019
- Series A, B and C funding captured 38% of the total funding invested, down from 73% in H1 2019
 - Series A closed \$152M, down 52% YoY
 - Series B closed \$397M, down 63% YoY
 - Series C closed \$165M, down 82% YoY
- Late stage deals captured \$600M, up 22% compared to H1 2019
- Exit: While most of the deals remain undisclosed, the value share of disclosed deals is up 52% YoY.



ASIA PACIFIC

ASIA PAC DEAL SIZE DISTRIBUTION


- *Attributed to the first half of the year uncertain environment, the value share of deals exceeding \$100 M lost momentum compared to 2019 and 2018*
- *While the majority of funding deals are still concentrated in deal size sub \$25M, there is a shift in preference for <\$1M to \$1-\$5M deals in recent years, which now accounts for 26% of all deals*
- *Deals of less than \$25M increased in volume, accounting now for 61% of all deals, up 3% from 2019*
- *Deals of \$50M and above represented 3% of all deals by volume, down 3% from 2019*



ASIA PACIFIC

QQQ ASIA PACIFIC HEALTHTECH DEAL VOLUME SHARE BY STAGE


- Quick Facts on Q2 2020 deal volume share:
 - 32% at Early stage, on par with vs Q1 2020 and up 10% vs Q2 2019
 - 59% at Growth stage, up by 13% vs Q1 2020 and up 5% vs Q2 2019.
 - Early Stage, Series A and Series B at Late stage, down by 56% $[9-4/9] \times 100 = 55.5 \approx 56\%$ vs Q1 2020 and Q2 2019.
 - Exits include 6 M&A and 3 IPOs
- Series B funding saw an upward trend in Q2 2020 while Series C and Late stage funding experienced a downward trend
- Series B funding accounted for more than 25% of all funding events



Note: Deals data exclude unspecified funding stage, Exits include M&A, IPOs and Post-IPO rounds


ASIA PAC HEALTHTECH PIPELINE 2020

- Quick Facts on the 2020 HealthTech pipeline:
 - No change:**
 - 24% of HealthTech startups were at Series A funding stage
 - 5% in Series C
 - 3% in Series D and beyond
 - 7% in Exits
 - Upward trend:**
 - Series B startups up 1%
 - Downward trend:**
 - 47% in Early Stage, down 1%



ASIA PACIFIC

ASIA PAC DIGITAL HEALTHTECH ECOSYSTEMS




Country	Regional Venture Share (%)	Cumulative Venture Funding (2015 - 2020 YTD)	Ventures per Capita (capita per million)	Cumulative Venture Deal Volume (2015 - 2020 YTD)
China	28.8%	19.6B	0.46	1192
India	25.5%	\$2.9B	0.42	520
Australia	10.2%	\$486M	9.05	139
Singapore	9.8%	\$490M	37.48	182
Japan	6.5%	1.1B	1.14	240

Source: HealthTech Alpha

ASIA PACIFIC

HEALTHTECH CATEGORY ATTRACTIVENESS


Medical Diagnostics continued to remain the hottest category and whilst most other categories cooled, Telemedicine and Wellness solutions experienced an uptick vs H2 2019







ASIA PACIFIC

CATEGORY FUNDING VARIANCE

With 21.9x, Telemedicine saw the largest YoY funding total increase, followed by Medical Diagnostics which doubled whereas overall category deal values decreased between 28% and 99% YoY




APAC Telemedicine Ecosystem Snapshot

	Teleconsultation	Telesurgery	Telepathology	Teleradiology
Business Model	B2B2C / B2C - focused		B2B-focused	
	Synchronous or asynchronous consultation by remote telecommunications, generally diagnosis or treatment of a patient at a site remote from the patient or primary physician to omit geographical and functional distance.	Use of wireless networking and robotic technology to allow surgeons to operate remotely on patients. Telesurgery benefits the shortage of surgeons and eliminates geographical barriers that prevent timely and high-quality surgical intervention, financial burden, complications, and risky long-distance travel.	Telepathology is the practice of pathology at a distance by using video imaging and telecommunications. Current telepathology applications include intraoperative frozen sections services, routine surgical pathology services, second opinions, and subspecialty consultations.	Teleradiology is the exchange of radiological images and patient-related data between geographically different locations for purposes of primary interpretation, expert consultation and/or clinical review by digital transmission.
Primary Value Proposition	Awareness, Treatment	Clinical Workflow	Diagnosis	
Ecosystem Volume	249	16	16	15
Sample Ventures				

ASIA PACIFIC

CATEGORY DEAL VOLUME VARIANCE

Medical Diagnostics exceeded H1 2019 by 53% leaving Medical Diagnostics to be the only category which surpassed 2019 in both value and volume, unlike all other categories, and leading to a 30% drop in the median variance



ASIA PACIFIC

HEALTHTECH MOST FUNDED CATEGORIES BY VALUE

Medical Diagnostics remained the most funded Digital Health category in H1 2020. The \$256M Genetron Health IPO accounts for almost 30% of funding in the category while Telemedicine moved up to 4th place



A NEW CATEGORY IS BORN


In an effort to manage and contain the pandemic within populations, governments are introducing applications to track and trace contamination and adapting data privacy laws

Singapore		Created by the Government Technology Agency (GovTech) in collaboration with the Ministry of Health (MOH), TraceTogether works by exchanging short-distance Bluetooth signals between mobile phones that have the app installed.
India		Aarogya Setu is a mobile application developed by the Government of India that is using Bluetooth technology to connect essential health services with the people of India in our combined fight against COVID-19.
China		In China, the government has used to used existing applications, including Alipay and WeChat and Tencent Healthcare to track people's interactions and perform contact tracing.
Indonesia		Designed by the Ministry of Information Communication and the Ministry of SOEs of Indonesia, the Peduli Lindungi application has been used by the Ministry of Health and Task Force in overcoming the COVID-19 pandemic.
Japan		Officially provided by the Ministry of Health, Labour and Welfare of Japan (MHLW), COCOA notifies you of close contact with COVID-19 positive users to help the government and healthcare organizations contain the spread of COVID-19.
Australia		COVIDSafe app has been developed by the Australian Government Department of Health to help keep the community safe from coronavirus (COVID-19).
Thailand		MorChana is a tool to assist Medical Staffs, Government Agencies, Business Owners developed by the Electronic Government Agency Thailand

ASIA PACIFIC

MOST ATTRACTIVE THERAPEUTIC FOCUS AREAS BY VALUE SHARE


Majority of total funding in each therapeutic area focus was in Growth stage. No doubt reflecting the pandemic, Infectious Diseases has in the past 6 months already surpassed FY 2019 by 65%, knocking out Mental Health



ASIA PACIFIC

MOST ATTRACTIVE THERAPEUTIC FOCUS AREAS BY VOLUME SHARE

For oncology-focused ventures, Series B deals represented more than 41% of all deals, up 64% YoY, while Series D and beyond deals for Diabetes focused ventures increased by 100% now accounting for 20%



ASIA PACIFIC

H1 2020 ASIA PAC MOST ACTIVE INVESTORS

Investors in China prudently deployed venture capital into HealthTech in China, whilst, in contrast, the most active investors were located in North East Asia, more specifically South Korea

Investor	Type	Country	2020 HealthTech Deals	Cumulative Number of HealthTech Deals	Latest Participated Investment	Amount Raised
NAVER D2 Startup Factory	Accelerator	South Korea	4	7	ichrogene (아이크로진)	\$0.9 M
TIPS	Accelerator	South Korea	4	27	M2S (엠투에스)	\$0.4 M
Sequoia Capital China	VC	China	3	52	Miaoshou (妙手医生)	\$84.6 M
Morningside Venture Capital	VC	China	3	27	Keep (Keep)	\$80 M
Legend Capital	VC	China	3	24	Deep Informatics (迪英加)	\$14.0 M
SMBC Venture Capital	VC	Japan	3	17	Modulus (모듈러스)	\$25.3 M
SIG	VC	China	3	14	Lead Medical (立达融医)	\$1.4 M
Aflac Innovation Partners	CVC	Japan	3	13	Mental Health Technologies (멘탈헬스 테크놀로지스)	\$2.25 M
Sequoia Capital India	VC	India	3	6	Qure.ai	\$16 M

ASIA PACIFIC


H1 2020 EXITS

M&A				
Startup	Country	Date	Deal Size	Acquired by
Genesky (天昊基因)	China	1/2020	undisclosed	NuProbe (格微基因)
Jaga-me	Singapore	1/2020	undisclosed	Alliance Healthcare Group
Mecompany (ミーカンパニー)	Japan	2/2020	undisclosed	JMDC
Doc Care	India	3/2020	undisclosed	Healwell24
FitMeIn	India	5/2020	undisclosed	HealthAssure
Baikemy (百科名医)	China	5/2020	undisclosed	ByteDance

IPO				
Startup	Country	Date	Deal Size	Listed on
Medical MOOC (医学慕课)	China	2/2020	\$12 M	NASDAQ
Burning Rock Dx (燃石医学)	China	6/2020	\$247.8 M	NASDAQ
Genetron Health (泛生子)	China	6/2020	\$256 M	NASDAQ

Note: For further information visit HealthTech Alpha

HEALTHTECH STARTUP FUNDING LIFE CYCLE KEY METRICS (2020)



Note: "Med" indicates median



Note: (1) Percentages in bubbles represent delta vs FY 2019 (2) Mid stage arrows indicate whether time between stages has increased or decreased vs FY 2019 (3) Startup age is median and cumulative

Note: Range indicates the range between the 1st Quartile and the 3rd Quartile and therefore eliminates outliers

ASIA PACIFIC




H1 2020 HEALTHTECH PARTNERSHIPS

In the first half of 2020, 103 partnerships have been announced with pharma and insurance accounting for 28%, primarily focused on China with significant domestic activity in Japan










ASIA PACIFIC

H1 2020 HEALTHTECH PARTNERSHIPS



ASIA PACIFIC

H1 2020 NOTEWORTHY INSURANCE PARTNERSHIPS

Corporate	Startup	Location	Date	Category
 Prudential	 MyanCare telemedicine	Myanmar	1/2020	Teleconsultation
 FWD insurance	 naluri.	Malaysia	2/2020	Digital Therapeutics
 Aflac	 Reason Why (リーズンホワイ)	Japan	3/2020	Medical Concierge
 AXA mandiri	 halodoc	Indonesia	4/2020	Consumer Marketplace
 泰康人寿 TAIKANG LIFE	 妙more 健康	China	5/2020	Corporate Health

ASIA PACIFIC

H1 2020 NOTEWORTHY PHARMACEUTICAL PARTNERSHIPS

Corporate	Startup	Location	Date	Category
 Sinopharm	 OrigiMed (至本医疗)	China	2/2020	Genomics-related Diagnosis
	 Liangyihui (良医汇)	China	2/2020	Health Information Platform
	 Nuohui Medical (诺惠医疗)	China	2/2020	Medical Payments
 Astellas Pharma	 Insilico Medicine	Hong Kong	5/2020	Drug Discovery
	 We Doctor (微医)	China	1/2020	Integrated Solutions
 AstraZeneca	 eko.ai	Singapore	2/2020	Diagnosis Tools
	 MDHcare (易得好康)	China	3/2020	Genomics-related Diagnosis
 Suzuken	 Embrace (エンブレース)	Japan	2/2020	Hospital
 Daewoong Pharmaceutical	 GenomicTree (지노믹트리)	South Korea	3/2020	Genomics-related Diagnosis

ASIA PACIFIC

H1 2020 OTHER NOTEWORTHY PARTNERSHIPS

Partner	Startup	Location	Date	Category
 Alibaba Cloud (Tech)	 BGI Genomics (华大基因)	China	1/2020	Genomics-related Diagnosis
 Celcom (Telecommunication)	 DoctorOnCall	Malaysia	2/2020	Teleconsultation
 Gojek (Tech)	 Halodoc	Indonesia	3/2020	Online Marketplace
 Tencent Trusted Doctors (企鹅杏仁) (Digital Health venture)	 Easyhin (妈咪知道)	China	4/2020	Teleconsultation
 We Doctor (微医) (Digital Health venture)	 BookDoc Connect & Unite	Malaysia	5/2020	Teleconsultation
 Sony (Tech)	 Vuno (뷰노)	South Korea	6/2020	Medical Imaging

ASIA PACIFIC

A person is sitting on the edge of a large, dark, rocky cliff on the right side of the image. They are looking out over a vast, dense cityscape that stretches to the horizon. The city is filled with numerous high-rise buildings and residential blocks. In the background, a body of water is visible, and the sky is hazy. The overall scene conveys a sense of height and perspective.

OUR POINT OF VIEW

OUR POINT OF VIEW

The Asia Pac HealthTech ecosystem demonstrated strong resilience during the pandemic with the first half of 2020 closing at US\$1.9B invested, across 171 deals.

Having weathered geopolitical headwinds throughout most of 2019, the Asia Pac region was, as early as January, impacted by the Covid-19 pandemic and unprecedented government measures to mitigate the pandemic. The first quarter closed at a meagre US\$761M and was its lowest recorded since 2016. The second quarter bounced back recording US\$1.1B, with deal value ending the first half down 46% versus H1 2019, with a corresponding deal volume decline of 20%. The average deal size was US\$10.9M, down 33% YoY.

Despite a Growth stage deal collapse, Late stage deals grew: Early stage deal volume share held its nerve to remain flat with a dip of 7% in total deal value. Despite the volume share of Growth stage deals increasing, their corresponding deal value share is down 67% primarily driven by Series B and C total deal value collapsing by 63% and 82% respectively. The silver lining in this storm is Late stage deals which captured US\$600M, up 22% versus H1 2019.

China shrinks, and in contrast, India and NEA grow: Accountable for 60% of total Asia Pac HealthTech funding by value (down from 70%), dollars to VC-backed ventures in China shrunk 57% in H1 2020 YoY. Compounding the geopolitical headwinds and a slowing domestic economy, the pandemic has spooked investors yet further.

India's 2019 momentum continued unabated and saw the country register its largest first half funding on record, closing at US\$362M, driven by a growing deal volume. India HealthTech has seemingly sailed through the pandemic unscathed so far. New in our H1 2020 report, our **NE Asia** analysis where the sub-region bucked the trend with total funding in digital health jumping to US\$240M, up 33% from H1 2019.

SE Asia total funding sunk 50% with Singapore recording all the significant deals.

Telemedicine reshuffle the top most attractive categories: Reflecting the pain points experienced by health systems during the pandemic, Medical Diagnostics maintained its pole position with Wellness, Patient Solutions, and Telemedicine stepping into the top 4 in H1 2020, with the latter recording a funding variance of 22x YoY.

Infectious Diseases is the new kid on the block: We continue our analysis of which specific diseases are attracting the most invested dollars. Oncology, Diabetes and Cardio Vascular maintain their top 3 positions. Infectious Diseases and Neurology step up into the top 5 knocking out Mental Health. We fully expect Mental Health to bounce right back into a leading position as the effects of the pandemic and lockdowns on society are felt.

Accounting for over 28%, pharma and Insurers are the most active builders of partnerships: China is the focal point for these partnerships particularly for MNCs although we would be remiss if we did not highlight the impressive number of primarily domestic partnerships in Japan. It is interesting to note that the focus of these partnerships is Diagnosis, Online Market Places and Medical Education.


Industry and investor sentiment for HealthTech in Asia Pac remains upbeat: Business leaders described digital health as a high priority and are planning to build further partnerships. Although investors have significantly slowed their investments in the first half, most have declared their intention to make investments in HealthTech in Asia Pac in H2 2020.

Despite an unprecedented environment, the Asia Pac HealthTech ecosystem has shown great resilience: Galen Growth expects the Asia Pac HealthTech ecosystem to bounce back in H2 2020 as payors, manufacturers and health system leaders seek to expedite solving the many pain points highlighted by the pandemic.


POINT OF VIEW

H1 2020 HEALTHTECH CORPORATE SENTIMENT

IMPORTANCE OF HT TO MY ORGANIZATION




CLEARLY DEFINED HT STRATEGY IN H1 2020




PARTNERSHIPS BUILT IN H1 2020




SET UP TO ENGAGE SUCCESSFULLY W/ HT



BULLISHNESS IN H2 VS H1 2020



BUILD PARTNERSHIPS IN H2 2020




Source: Galen Growth - HealthTech Sentiment Survey – June 2020


POINT OF VIEW

H1 2020 HEALTHTECH INVESTOR SENTIMENT


IMPORTANCE OF HT IN H2 VS H1 2020




IS COVID-19 IMPACTING DEAL FLOW




INVESTMENTS IN HT IN H1 2020




HAS COVID-19 IMPACTED YOUR INVESTING



BULLISHNESS IN H2 VS H1 2020



INVESTING IN HT IN H2 2020




Source: Galen Growth - HealthTech Sentiment Survey – June 2020


POINT OF VIEW

H1 2020 HEALTHTECH STARTUP SENTIMENT


IMPORTANCE OF HT IN H2 VS H1 2020




HAS H1 2020 BEEN POSITIVE FOR YOU?




RAISING IN H2 2020



HAS COVID-19 IMPACTED YOUR GROWTH?




BULLISHNESS IN H2 VS H1 2020



Source: Galen Growth - HealthTech Sentiment Survey – June 2020

HEALTHTECH REGULATORY SHIFT

Governments across the region have fast-tracked the introduction or modification of regulations to accelerate the adoption of digital health solutions to fix their highly stretched and stressed health systems




CHINA

Integration of track & trace to existing platforms such as AliPay or WeChat

Free telemedicine consultation via major HealthTech players

High adoption of online hospitals with, e.g. Ali Health reporting a growth of 900% between Dec 2019 and Jan 2020



JAPAN

Launch of free telemedicine consultation by existing platforms

Loosening of national restrictions of online drug delivery (e.g. via drop-off at the nearest pharmacy)

Increased number of Medical Imaging partnerships to develop AI-based solutions for the screening of COVID-19 using chest x-rays



SOUTH KOREA

Expanded use of remote patient triage by hospitals

Temporary lift of ban of telemedicine and e-prescription solutions

Launch of a public Corona Map to inform on cases and their movements and a Mask Map to locate stores where surgical masks are available



AUSTRALIA

Launch of an educational app to inform the public about COVID-19 by the Australian Digital Health Agency

Additional \$310M in new telehealth measures and incentives for doctors. The package includes opening telehealth & telephone to all Australians

Expanded use of remote patient triaging by hospitals



India

Publication of the Telemedicine Practice Guidelines to enable registered practitioners to provide healthcare using telemedicine

Launch of a triple helix task-force with R&D labs, academia, start-ups, and industries to identify technological advancements related to COVID-19

Launch of the Action Covid Team (ACT) grant to seed into Scalable pandemic eradication ideas

CHINA

INVESTMENT TRENDS




CHINA - HEALTHTECH OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



Telemedicine	13%
Patient Solutions	11%
Wellness	11%
Research	11%
Health Management Solutions	11%
Research	11%
Medical Education	7%
Remote Monitoring	7%
Others	17%

CHINA - INVESTMENT TRENDS


CHINA - HEALTHTECH FUNDING HISTORY

- The first half of 2020 recorded a total of \$1.15 B compared to \$2.7B in H1 2019, down 57%
- With 52 deals executed in H1 2020, investment volume is also down 32% vs H1 2019
- Despite funding activity lagging behind H1 2019, Q2 significantly increased compared to Q1 both in terms of volume (up 48% QoQ) and value (2.76x QoQ)
- In addition to recording lower deal volume and value, average deal size decreased further to \$22.1M, down 37% vs H1 2019, significantly impacted by less mega deals (-7)
- Cumulative deal value since 2017: \$14.2B

Cumulative Deal Volume by Quarter

	Q1	Q2	Q3	Q4
2017 Deals	58	118	179	250
2018 Deals	65	132	195	254
2019 Deals	41	77	107	126
2020 Deals	21	52		


Cumulative Deal Value by Quarter



CHINA - INVESTMENT TRENDS

QQQ - CHINA HEALTHTECH FUNDING HISTORY


- The first half of 2020 recorded the lowest deal count since 2017 with a 32% decrease compared with H1 2019
- Funding activity by value in Q1 2020 was the lowest on record since 2017 with a total of \$306 M
- Mega deals in China in H1 2020 accounted for 57% of all funding deployed, on par with 2019
- Despite the difficult geopolitical and pandemic environment, funding in Q2 bounced back, largely driven by the Genetron Health and Burning Rock Dx IPOs in June



CHINA - INVESTMENT TRENDS

QQQ - CHINA HEALTHTECH DEAL VOLUME SHARE

- Navigating an uncertain environment, young digital health ventures increasingly struggled to raise capital with Early Stage funding continuing to decrease
- Quick Facts on Q2 2020 deal volume share:
 - 10% at Early stage, on par with Q1 2020 and down 9% vs Q2 2019
 - 71% at Series A, Series B and Series C stage, up 15% vs Q1 2020 and down 8% vs Q2 2019
 - 10% at Late stage, down 47% vs Q1 2020 and up 25% vs Q2 2019
- Overall, digital health exits in China became more prominent with Genetron Health and Burning Rock Dx listing in H1 2020 and 2 digital health ventures being acquired




Note: Deals data exclude unspecified funding stage

CHINA - INVESTMENT TRENDS

CHINA - HEALTHTECH MOST FUNDED CATEGORIES BY VALUE


Medical diagnostics remained the most invested category for the past 6 months both by value and by volume with, as runner up, while Telemedicine moved up to 3rd place



CHINA - INVESTMENT TRENDS

CHINA - DEAL SIZE DISTRIBUTION

- *Share of deals of \$1-\$5M and \$10-\$25M grew in H1 2020 vs 2019 while <\$1M and \$25 - \$50M remained stable*
- *The share of mega-deals (>\$100M) fell in H1 2020 totalling 6%, down from 9% in 2019*



CHINA - INVESTMENT TRENDS

H1 2020 CHINA - MOST ACTIVE INVESTORS

Investor	Headquarter	# of Deals in 2020	Total Number of HealthTech Deals	Preferred Investment Stage	Largest Investee in China in 2020	Largest participated Deal in China in 2020
 Sequoia Capital China <small>红杉资本 CHINA</small>	Beijing, China	3	52	Growth	Miaoshou (妙手医生)	\$84.6 M
 Morningside Venture Capital <small>晨兴资本</small>	Shanghai, China	3	27	Growth	Keep (Keep)	\$80 M
 Legend Capital <small>君联资本</small>	Beijing, China	3	24	Growth	Deep Informatics (迪英加)	\$14 M
 SIG <small>SUSQUEHANNA</small>	Philadelphia, United States	3	14	Growth	ZY Health (智云健康)	\$143.4 M
 Qiming Venture Partners <small>启明创投</small>	Shanghai, China	3	29	Growth-Late	Miaoshou (妙手医生)	\$84.6 M

CHINA - INVESTMENT TRENDS

H1 2020 CHINA - HEALTHTECH MEGA DEALS



Genetron Health (泛生子)

IPO


Medical Diagnostics



Burning Rock Dx (燃石医学)

IPO

Medical Diagnostics



ZY Health (智云健康)

Series D

Online Marketplace

SOUTH ASIA


A woman is shown from the chest up, with her arms raised and hands held flat against a light-colored wall. Her hands and forearms are covered in red and green paint. She is wearing a patterned sari. The lighting is dramatic, with strong shadows and highlights.

INVESTMENT TRENDS


SOUTH ASIA - INVESTMENT TRENDS

SOUTH ASIA - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



SOUTH ASIA - INVESTMENT TRENDS


SOUTH ASIA - HEALTHTECH FUNDING HISTORY

- H1 2020 HealthTech funding in South Asia closed at \$363M, up 2% vs H1 2019 and up 82% vs H1 2018, driven by India
- The first quarter of 2020 in South Asia saw the highest total funding by value since 2017
- While funding volume was up 9% YoY, it remained on a much lower level as compared to the first half year periods in 2018 and 2017
- Average deal size in H1 2020 dipped marginally to \$9.55M, down 6% compared to H1 2019, but up 3x compared to H1 2018.
- South Asia counted 1 mega deal in H1 2020

Cumulative Deal Volume by Quarter


	Q1	Q2	Q3	Q4
2017 Deals	32	68	90	112
2018 Deals	32	63	96	117
2019 Deals	14	35	55	74
2020 Deals	17	38		

Cumulative Deal Value by Quarter




INDIA - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



INDIA - INVESTMENT TRENDS


INDIA - HEALTHTECH FUNDING HISTORY

- H1 2020 represented the largest first half year in India till date, closing at \$362M, up 2% YoY
- With more than \$250M invested, Q1 2020 funding in India saw its greatest funding since 2017
- With 37 deals executed, H1 2020 picked up from 2019, up 19% YoY, but it is still 38% and 44% down vs H1 2018 and H1 2017, respectively.
- Average deal size in H1 2020 fell to \$9.78 M, down 15% compared to H1 2019, but up 3x compared to H1 2018.
- Cumulative deal value since 2017 is \$2.1 B

Cumulative Deal Volume by Quarter

	Q1	Q2	Q3	Q4
2017 Deals	30	66	88	107
2018 Deals	30	60	91	111
2019 Deals	12	31	51	69
2020 Deals	16	37		


Cumulative Deal Value by Quarter



INDIA - INVESTMENT TRENDS

QOQ INDIA - HEALTHTECH FUNDING HISTORY


- After a strong Q4 2019 finish, funding in India slowed down in Q1 and Q2, yet, total funding in H1 2020 exceeded H1 2019 both in terms of total volume of deals and total value invested
- Funding activity by volume also increased YoY, exceeding H1 2019 by 19%
- The \$110M Series D2 funding round in Wellness platform cure.fit, represented 30% of the total funding invested in H1 2020



INDIA - INVESTMENT TRENDS

QOQ INDIA - HEALTHTECH DEAL VOLUME SHARE

- Quick Facts for Q2 2020 deal volume share:
 - 62% at Early stage, up 24% vs Q1 2020 and up 3x vs Q2 2019
 - 29% at Growth stage, down 6% vs Q1 2020 and down 22% vs Q2 2019
 - 5% at Late stage, down 61% vs Q1 2020 and down 81% vs Q2 2019
- Early stage deals continued to gain for the second consecutive month, rising to its highest share since Q2 2018
- Growth stage deals remained below 1/3 of all deals demonstrating a lack of Growth stage investment in India
- Exits: India recorded 2 M&A deals




Note: Deals data exclude unspecified funding stage

INDIA - INVESTMENT TRENDS

INDIA - HEALTHTECH MOST FUNDED CATEGORIES BY VALUE


Wellness captured the most funding in India in H1 2020, primarily driven by a single investment in Cure.fit in Q1 2020



INDIA - INVESTMENT TRENDS

INDIA - DEAL SIZE DISTRIBUTION

- *Share of deals of <\$1M increased in H1 2020 now representing 25% of all deals closed; With a rising number of Early stage deals, deal size <\$1M increased in share*
- *Number of deals between \$25M and \$50M remained flat whilst rounds up to \$100M increased to their highest volume share*
- *Number of deals of \$100M and above remained low in volume in H1 2020, performing worse than 2019, reflecting low volume of mega deals in India*








*Note: Annual totals do not add up to 100% due to undisclosed deals




INDIA - INVESTMENT TRENDS

H1 2020 INDIA - MOST ACTIVE INVESTORS

Investor	Headquarter	# of Deals in 2020	Total Number of HealthTech Deals since 2012	Preferred Investment Stage	Largest Investee in 2020	Largest participated Deal in 2020
 Bessemer Venture Partners	United States	2	33	Early	DocsApp	\$20 M
 Chiratae Ventures	India	2	23	Early	HealthPlix	\$6 M
 Accel Partners	United States	2	23	Early	Consure Medical	\$4.7 M
 Blume Ventures	India	2	11	Early	HealthAssure	\$0.8 M
 Rebright Partners	India	2	7	Growth	DocsApp	\$20 M

INDIA - INVESTMENT TRENDS

H1 2020 INDIA - HEALTHTECH TOP 5 MOST NOTABLE DEALS



SE ASIA (SEA)

INVESTMENT TRENDS


- Singapore
- Indonesia
- Malaysia
- Myanmar
- Vietnam
- Thailand
- Philippines
- Other SEA




SOUTH EAST ASIA - INVESTMENT TRENDS

SEA - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



- Wellness 16%
- Telemedicine 13%
- Health Management Solutions 10%
- Remote Monitoring 10%
- Health Services Search 9%
- Patient Solutions 8%
- Medical Education 8%
- Medical Diagnostics 5%
- Others 21%

SOUTH EAST ASIA - INVESTMENT TRENDS


SEA - HEALTHTECH FUNDING HISTORY

- With 14 deals recorded in the first half of 2020, funding volume was the lowest since 2017, recording a drop of 60% YoY
- By value, the region funding value closed at \$94M, down by 47% as compared to H1 2019
- Major deals recorded for the region are all in Singapore
- Despite less funding activity average deal size in H1 2020 increased to \$6.74 M, up 34% compared to H1 2019, and up 3.1x compared to H1 2018
- Cumulative deal value since 2017 is \$575 M

Cumulative Deal Volume by Quarter

	Q1	Q2	Q3	Q4
2017 Deals	11	29	41	51
2018 Deals	11	27	42	58
2019 Deals	18	35	46	52
2020 Deals	6	14		

Cumulative Deal Value by Quarter




Note: Previous Winners of the GGA annual Most Innovative HealthTech Startup award

SOUTH EAST ASIA - INVESTMENT TRENDS

QOQ SEA - HEALTHTECH FUNDING HISTORY


- After a weak first quarter, Q2 2020 witnessed a small uptick of funding by volume after two quarters of 6 deals each
- Generally, funding volume remained low level compared to previous years
- Despite lower funding activity, the quarterly funding value remained at around \$50M per quarter



SOUTH EAST ASIA - INVESTMENT TRENDS

QOQ SEA - HEALTHTECH DEAL VOLUME SHARE

- Quick Facts for Q2 2020 deal volume share:
 - 38% at Early stage, up 15% vs Q1 2020 and down 19% vs Q2 2019
 - 63% at Growth stage, up 26% vs Q1 2020 and up 34% vs Q2 2019
 - No Series C and late stage deals were recorded in H1 2020
- Early stage deals in H1 2020 continued to shrink, now representing 38% of all investments, down 9% compared to H1 2019
- Whilst total Early stage deal volume share regained 5% QoQ, now representing more than 1/3 of all deals again, Growth stage deals continued to gain momentum, now representing a 63% share of H1 2020, the highest share since 2017



Note: Deals data exclude unspecified funding stage

SOUTH EAST ASIA - INVESTMENT TRENDS

SEA - HEALTHTECH MOST FUNDED CATEGORIES BY VALUE


In an environment with lower deal activity during the first half of 2020, Telemedicine emerged as the top invested category by value, largely from the Singapore's Doctor Anywhere's Series B \$27M deal



SEA - HEALTHTECH DEAL VOLUME SHARE BY COUNTRY

Singapore was the major driver of funding invested in SEA in H1 2020 with Singapore accounting for 5 of the largest deals in the region

- By deal volume share, Singapore kept its lead in the sub-region with 57% share, though shrinking from 60% in H1 2019 as neighbouring countries expand their ecosystem and its attractiveness
- In an environment with generally less deal activity in H1 2020, Malaysia accounted for more than 21% of all deals in SEA
- The Philippines, Thailand and Myanmar have not recorded any deals in H1 2020






Note: Only countries with recorded deals represented

SOUTH EAST ASIA - INVESTMENT TRENDS

H1 2020 SEA – MOST ACTIVE INVESTORS

28 individual investors invested in Digital Health ventures in SEA of with only two invested at least twice

Investor	Headquarter	# of Deals in 2020	Cumulative Number of HealthTech Deals	Preferred Investment Stage	Largest Investee in 2020	Largest participated Deal in 2020
 EDBI	Singapore	2	14	Growth	Doctor Anywhere	\$27 M
 Genesia Ventures	Japan	2	4	Early	BuyMed	\$2.5 M
 Optum Ventures	United States	1	15	Growth	Holmusk	\$21.5M

*Note: Only 2 investors invested more than once in Digital Health in SEA in H1 2020

SOUTH EAST ASIA - INVESTMENT TRENDS

H1 2020 SEA - HEALTHTECH TOP 5 MOST NOTABLE DEALS



NORTH EAST ASIA


A city skyline at sunset with a purple and orange sky. The buildings are silhouetted against the bright, colorful sky. The sky transitions from a deep purple at the top to a bright orange near the horizon. The city buildings are of various heights and styles, with some prominent skyscrapers in the center.

INVESTMENT TRENDS


- Japan
- South Korea
- Taiwan
- Hong Kong

NEA - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE




JAPAN - HEALTHTECH ECOSYSTEM OVERVIEW

KEY INNOVATION NODES




Powered by Bing
© GeoNames, Microsoft, TomTom

NUMBER OF HEALTHTECH VENTURES




CATEGORY DISTRIBUTION SHARE




SOUTH KOREA - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



NORTH EAST ASIA - INVESTMENT TRENDS


NEA - HEALTHTECH FUNDING HISTORY

- Total funding for North East Asia (NEA) closed at \$240 M in H1 2020, up 33% from H1 2019
- Unlike other sub-regions in Asia Pac, NEA demonstrated strong deal count resilience, closing H1 2020 at 63, its highest count ever
- Japan and South Korea remained the strongest ecosystem drivers in NEA
 - Total funding in Japan reached \$12 M, doubling its H1 2019 investment
 - Total funding in South Korea exceeded \$118M, on par with H1 2019
- Average deal size in H1 closed at \$3.8M, up 16% YoY
- Cumulative deal value since 2017 is \$1.6B

Cumulative Deal Volume by Quarter

	Q1	Q2	Q3	Q4
2017 Deals	13	33	61	85
2018 Deals	27	55	84	123
2019 Deals	31	55	91	130
2020 Deals	34	63		


Cumulative Deal Value by Quarter



NORTH EAST ASIA - INVESTMENT TRENDS

QQQ NEA - HEALTHTECH FUNDING HISTORY


- Despite a slow down in funding activity in Q2 as compared to the previous quarters, the first two quarters exceeded last years quarters, both in terms of total volume and total value
- Funding by deal volume in H1 has increased by 15% as compared to H1 2019 and H1 2018



NORTH EAST ASIA - INVESTMENT TRENDS

QOQ NEA - HEALTHTECH DEAL VOLUME SHARE

- Quick Facts for Q2 2020 deal volume share:
 - 31 % at Early stage, down 18% vs Q1 2020 and down 3% vs Q2 2019
 - 69% at Growth stage, up 23% vs Q1 2020 and up 17% vs Q2 2019
 - No Series D and Beyond or Exit Stage deals were noted
- By volume share, early stage funding has constantly decreased from more than 50% of all deals in 2018 to less than 1/3 in Q2 2020
- Growth Stage investment has expanded, now accounting for more than 2/3 of all investments



Note: Deals data exclude unspecified funding stage

NORTH EAST ASIA - INVESTMENT TRENDS

NEA - HEALTHTECH MOST FUNDED CATEGORIES BY VALUE


While Medical Diagnostics raced from 3rd to the first position of the most funded categories in H1 2020, Health Management Solutions dropped to 4th after recording a drop of 83% in funding compared to H1 2019



NORTH EAST ASIA - INVESTMENT TRENDS

NEA - HEALTHTECH DEAL VOLUME SHARE BY COUNTRY

- With both countries recording more deals than in H1 2019, Japan and South Korea accounted for 98% of all deals in NEA, up 2% YoY
 - South Korea recorded for approximately 58% of all deals, up 6% YoY
 - Japan recorded for approximately 41% of all deals, marginally down by 3%
- While Taiwan has recorded 1 deal in H1 2020, no deal has been disclosed in Hong Kong
- Japan and South Korea strengthened their positions, demonstrating a maturing digital health ecosystem



Note: Only countries with recorded deals represented


NORTH EAST ASIA - INVESTMENT TRENDS

H1 2020 NEA - MOST ACTIVE INVESTORS

Investor	Type	Headquarter	# of Deals in 2020	Cumulative Number of HealthTech Deals	Preferred Investment Stage	Largest Investee in 2020	Largest participated Deal in 2020	
 D2 STARTUP FACTORY NAVER	NAVER D2 Startup Factory	Accelerator	South Korea	4	7	Early	Ichrogene (아이크로진)	\$0.9 M
 TIPS	TIPS	Accelerator	South Korea	4	27	Early	n.Cer (엔서)	\$0.4 M
 SMBC Venture Capital	SMBC Venture Capital	VC	Japan	3	17	Early	Modulus (모듈러스)	\$25.3 M
 NH투자증권 NH INVESTMENT & SECURITIES	NH Investment & Securities	VC	South Korea	3	10	Growth	Lunit (루닛)	\$24.2 M
 SUZUKEN	Suzuken	CVC	Japan	3	5	Growth	Susmed (사스메드)	undisclosed
 theventures	The Ventures	VC	South Korea	3	5	Early	Genealogy (지니얼로지)	\$0.4 M

NORTH EAST ASIA - INVESTMENT TRENDS

H1 2020 NEA - HEALTHTECH TOP 5 NOTABLE DEALS




AUSTRALIA – NEW ZEALAND (ANZ)

INVESTMENT TRENDS




ANZ - HEALTHTECH ECOSYSTEM OVERVIEW


KEY INNOVATION NODES



NUMBER OF HEALTHTECH VENTURES



CATEGORY DISTRIBUTION SHARE



ANZ - INVESTMENT TRENDS


ANZ - HEALTHTECH FUNDING HISTORY

- Total funding for ANZ in H1 2020 closed at \$14 M, with no funding disclosed in Q2 2020, down 63% YoY
- Average deal size was \$4.7M up 23% compared to H1 2019
- Similarly to Europe, a significant proportion of total funding into Australian digital health ventures is achieved through grants
- Cumulative deal value since 2017 is \$313M

Cumulative Deal Volume by Quarter


	Q1	Q2	Q3	Q4
2017 Deals	5	15	21	32
2018 Deals	10	17	20	27
2019 Deals	4	10	12	18
2020 Deals	3	3		

Cumulative Deal Value by Quarter



ANZ - INVESTMENT TRENDS

QOQ ANZ - HEALTHTECH FUNDING HISTORY



ANZ - INVESTMENT TRENDS

QOQ ANZ - HEALTHTECH DEAL VOLUME SHARE

- Quick Facts for Q1 2020 deal volume share:
 - 33% at Early stage, up 16% vs Q4 2019 and up 33% vs Q1 2019
 - 33% at Growth stage, same vs Q4 2019 and down 17% vs Q1 2019
 - No late stage recorded
- No Series C and Late stage funding recorded since Q2 2017



Note: Deals data exclude unspecified funding stage

KEY INFORMATION



KEY INFORMATION

IMPORTANT INFORMATION

WHAT WE DEFINE AS HEALTHTECH

HealthTech defines the intersection between healthcare and technology and is also sometimes referred to as digital health. We recommend reviewing our taxonomy on slide 83 for further details.

HealthTech does not include Biotech, such as protein research or pharmaceuticals, and also does not include MedDev, such as devices that are implanted into the body.

WHAT INFORMATION DO WE TRACK

Galen Growth tracks a comprehensive inventory of key data points ranging from company demographics, funding and valuation to in-market capabilities on a continuously growing and curated list of HealthTech ventures drawn from all markets in Asia Pacific. We recommend reviewing our venture spotlights for further insights.

KEY TERMS / DEFINITIONS

- The report's base currency is USD
- Early stage includes all deals up to & including Pre-A stage
- Growth stage includes all deals at Series A, B & C stage
- Late stage includes all deals at Series D & beyond stage
- Exits include all IPO and M&A deals

WHERE DO WE SOURCE OUR INFORMATION

Galen Growth collates its data from primary research, public domain sources (press releases and news), proprietary analytics and from its unique network. The information is:

- Both disclosed and undisclosed by nature
- Continuously updated with the latest data
- Curated from both direct and indirect verified sources
- Augmented with our proprietary algorithms

Each HealthTech Alpha Index and Score is calculated using proprietary algorithms and data points drawn from our carefully curated HealthTech Alpha database.

IMPORTANT INFORMATION

This report is provided for informational purposes only and was prepared in good faith on the basis of public information available at the time of publication without independent verification.

Galen Growth does not guarantee or warrant the reliability or completeness of the data nor its usefulness in achieving any particular purposes. Numbers will be updated from time to time to reflect information identified after the event.

Galen Growth shall not be liable for any loss, damage, cost or expense incurred by reason because of any persons use or reliance on this report. This report is a proprietary aggregation of publicly available and undisclosed data and shall not be forwarded or reproduced without the prior written consent of Galen Growth.

KEY INFORMATION

OUR TAXONOMY

**Health Services Search**

Medical Concierge
Medical Tourism
Track & Trace
Triage

**Online Marketplace**

Consumer Marketplace
Professional Marketplace
On-demand Lab Tests

**Online Health Communities**

Patient Health Forums
Physician Networks
Other HCP Networks

**Health InsurTech**

Health Claim Management
Medical Payments
Health Insurance

**Medical Diagnostics**

Medical Imaging
Diagnosis Tools
Genomics Related Diagnosis

**Research**

Drug Discovery
Next Generation Sequencing
Genomics Related Research
Clinical Trials

**Remote Monitoring**

Home Healthcare
Remote Monitoring Devices
Care Coordination

**Medical Education**

HCP Education
Health Information Platform
Consumer Education

**Wellness**

Wellness Apps
Wearables
Smart Equipment
Wellness Information Platform
Genomics Related Applications

**Veterinarian**

Health Forums
Animal Imaging
Animal Monitoring

**Patient Solutions**

Digital Therapeutics
Patient Self-Diagnosis
Disease Management

**Health Management Solutions**

EHR / EMR
Physician / Clinic
Hospital
Pharmacy
Prescriptive Analytics

**Telemedicine**

Teleconsultation
Teleradiology
Telepathology

**Population Health Management**

Corporate Health
Integrated Solutions

**Others**

Social Enterprise
HCP Job Board
Software Provider
Contamination Management

ABOUT GALEN GROWTH

Galen Growth is the global leader in digital health intelligence, analytics and matchmaking, empowering global Fortune 500 companies and institutional investors to fast track their growth strategies.

OUR MISSION

Fast Tracking your HealthTech Innovation Ambitions

It is an external game! The most innovative companies use platforms to gain access to different capabilities and sources of data which they then use to build new business models or develop new products and services.

We believe the fastest, most effective way to scale digital health innovation is to be the preferred innovation partner for investors, corporations and startups to enable them to re-invent healthcare and realise its full societal value.

Galen Growth is the only trusted expert dedicated to digital health innovation across the entire value chain of healthcare: from R&D to payments. We partner with proven HealthTech ventures, Fortune 500 companies and leading investors to empower them to execute winning strategies.

With our unmatched Asian, USA and European coverage, we are the only innovation platform capable of bridging the ambitions of global headquarters and investor teams, to enable near term tangible business results.

OUR DIFFERENTIATORS

1

GLOBAL REACH

Unmatched global ecosystems coverage

- Unmatched and unequalled breadth, depth, accuracy and velocity of global data
- 4 regions, 6,300+ ventures, and 70+ million data points
- Unique global network of digital health innovation leaders
- Physical presence with offices in Asia and Europe

2

CORE SOLUTIONS

Cutting edge HealthTech innovation solutions

- **HealthTech Alpha:** Real-time data, analysis and news at your fingertips
- **Next Gen Scouting:** Problem statement driven scouting, selection and profiling
- **Acceleration Solutions:** Empowering enterprise innovation teams to win
- **Research:** Go-to-reference digital health research
- **Events:** Matchmaking dedicated to enterprise leaders, investors and startups

3

RECOGNISED SPECIALISTS

Proven team track record

- Preferred partner for many leading corporations and investors
- Trusted advisor with superb client credentials
- Specialist team with extensive industry leadership experience and proven track record

OUR CORE SOLUTIONS



NEXT GEN SCOUTING

SCOUT | SELECT | PROFILE

Scouting and profiling enabled by advanced analytics and insights

Leverage our analyst team and technology to fast track the analysis of hundreds of thousands of data points, way beyond financials, to pinpoint, evaluate and prioritise best fit ventures for your organisation's needs ahead of your peers.



HEALTHTECH ALPHA

MONITOR | IDENTIFY | TRACK

Real time data, analysis and news at your fingertips

The global leading on-demand HealthTech intelligence and analytics platform, preferred by enterprises, investors, startups and scale-ups, giving access to actionable insights and unique market intel on the thousands of digital health ventures enabling better decisions, based on real time and accurate data.



ENTERPRISE ACCELERATION










DESIGN | MOBILISE | BUILD

Empowering enterprise innovation teams to win

A full suite of cutting edge HealthTech acceleration programmes, powered by Galen Growth's unique capabilities, from Innovation Challenges to the Enterprise Innovation Programme to enable innovation leaders and their teams to fast track the design and execution of their organisation's digital health strategies.

ABOUT GALEN GROWTH

OUR PARTNERS

			Asia's Leading Life Insurer			
						
						
						

ABOUT GALEN GROWTH

SOLUTIONS OVERVIEW



HealthTech Alpha



Acceleration Solutions



Next Gen Scouting



Events



Research



ABOUT GALEN GROWTH

THE GALEN GROWTH DIFFERENCE




Monitor, evaluate and engage with the globe's HealthTech innovation ecosystems



Focus valuable resources on partnership deal execution for near term business impact versus the grind of research




Fast track your timelines to achieve earlier business impact



Develop real time actionable insights and transparency to the fast changing ecosystem



Start with the entire ecosystem picture versus a snapshot before zooming into best fit ventures



Build stronger capabilities and sustainable organisational knowledge



Operate with the most comprehensive and accurate data that is never out of date



Mitigate risks and avoid hype

Featured In

Bloomberg

**FIRSTLOOK
ASIA**



PharmaAsia
The voice of pharmaceutical manufacturing



**NIKKEI
ASIAN
REVIEW**

TECHINASIA

**938
NOW**
IN THE KNOW ON THE GO

THE EDGE
SINGAPORE

FT
FINANCIAL
TIMES

CIO
FROM IDG

MILKEN INSTITUTE
Changing the World in Innovative Ways



Thank You!

Reach out, Connect, Share, Like



galengrowth.com



twitter.com/galengrowth



linkedin.com/company/galen-growth



info@galengrowth.com